Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Intangibles (2016 - 2025)

Historic Change in Intangibles for Ani Pharmaceuticals (ANIP) over the last 13 years, with Q3 2025 value amounting to $60000.0.

  • Ani Pharmaceuticals' Change in Intangibles fell 9049.13% to $60000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 55196.42%. This contributed to the annual value of $717000.0 for FY2024, which is 9256.46% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Change in Intangibles of $60000.0 as of Q3 2025, which was down 9049.13% from $2.9 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Change in Intangibles high stood at $21.0 million for Q2 2021, and its period low was $4000.0 during Q4 2022.
  • In the last 5 years, Ani Pharmaceuticals' Change in Intangibles had a median value of $430000.0 in 2022 and averaged $3.7 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Change in Intangibles crashed by 9993.04% in 2021 and then skyrocketed by 6240000.0% in 2023.
  • Ani Pharmaceuticals' Change in Intangibles (Quarter) stood at $12000.0 in 2021, then plummeted by 66.67% to $4000.0 in 2022, then skyrocketed by 62400.0% to $2.5 million in 2023, then plummeted by 96.56% to $86000.0 in 2024, then tumbled by 30.23% to $60000.0 in 2025.
  • Its last three reported values are $60000.0 in Q3 2025, $2.9 million for Q2 2025, and $17.4 million during Q1 2025.